$500m-Plus Pours Into China Bioventures In A Week
$3bn JD Health IPO Planned
Executive Summary
From AI-assisted drug discovery to oncotherapy development, China has seen investment pour in over the past week, while the nation's largest online pharmacy is readying for a big Hong Kong debut.
You may also be interested in...
Argenx Advances Efgartigimod Into China With Zai Lab Pact
Having just filed efgartigimod in the US, the European biotech has signed up Zai Lab to help develop and sell the potential autoimmune blockbuster in China, where an estimated 200,000 people live with myasthenia gravis.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.